Cyprus for Biotech / Life Sciences

Cyprus ranks #7 of 25 jurisdictions for Biotech / Life Sciences on NomadSignal's scoring model, with an industry-weighted score of 65/100. The top strengths for Biotech / Life Sciences founders are family viability and operational ease. Whether it is the right choice depends on your funding stage, personal tax situation, and whether you are relocating alone or with a family.

Cyprus applies a statutory corporate tax rate of 12.5%, and an IP box regime at 2.5% for qualifying IP income. The jurisdiction has 65 active tax treaties. For Biotech / Life Sciences founders, corporate tax efficiency carries a 8% weight in the industry scoring model. Verify the current effective rate with a local advisor before making an incorporation decision.

Cyprus accesses EMA through EU membership via the Cyprus Medicines and Medical Devices Agency. Small patient population limits trial scale. IP Box extends to pharmaceutical patents at 2.5% effective rate. Used as an IP holding jurisdiction for pharma more than as an operational base. Cyprus offers a startup or entrepreneur visa pathway for qualifying founders. NomadSignal evaluates Biotech / Life Sciences-specific factors including Regulatory Approval Pathway, Clinical Trial Environment, Patent Regime for Biologics as part of the industry score. Check the country's official government and innovation agency websites for current program details.

Cyprus ranks #7 for Biotech / Life Sciences with 65/100. The #1 ranked jurisdiction is Singapore at 73/100. The gap is driven mainly by remote infrastructure, where Cyprus is weaker. Use NomadSignal's comparison pages to evaluate Cyprus head-to-head against specific alternatives.